News
VCYT
18.86
-0.32%
-0.06
Veracyte Announces 9 Abstracts Reinforcing The Value Of Decipher Prostate And Decipher Bladder Testing Will Be Presented At AUA 2024
Nine abstracts will be presented at AUA 2024, the annual meeting of the American Urological Association. Studies will evaluate the clinical utility of Veracyte's Decipher tests for patients with prostate or bladder cancer. The company is a leading cancer diagnostics company. The abstracts focus on its Decipher Prostate and Decipher Bladder Genomic Classifiers.
Benzinga · 2d ago
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Nine abstracts will be presented at AUA 2024, the annual meeting of the American Urological Association. Studies will evaluate the clinical utility of Veracyte’s Decipher tests in guiding treatment decisions for patients with prostate or bladder cancer. Other presentations will explore new insights into these cancers’ underlying biology.
Barchart · 2d ago
Weekly Report: what happened at VCYT last week (0408-0412)?
Weekly Report · 3d ago
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 4d ago
Weekly Report: what happened at VCYT last week (0401-0405)?
Weekly Report · 04/08 10:09
Weekly Report: what happened at VCYT last week (0325-0329)?
Weekly Report · 04/01 10:08
Weekly Report: what happened at VCYT last week (0318-0322)?
Weekly Report · 03/25 10:10
Weekly Report: what happened at VCYT last week (0311-0315)?
Weekly Report · 03/18 10:09
Weekly Report: what happened at VCYT last week (0304-0308)?
Weekly Report · 03/11 10:07
Veracyte: Statement of changes in beneficial ownership of securities
Press release · 03/06 00:07
Weekly Report: what happened at VCYT last week (0226-0301)?
Weekly Report · 03/04 10:09
Veracyte: Securities to be offered to employees in employee benefit plans
Press release · 03/01 04:15
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
Ark Invest sold over $17 million worth of Coinbase Global Inc (NASDAQ:COIN) shares on Wednesday. Ark Invest sold 86,298 shares of the cryptocurrency exchange for $17.33 million. The sale came in the backdrop of the trading platform's outage on the same day.
Benzinga · 02/29 04:02
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
Cathie Wood-led Ark Invest sold $9.3 million worth of Coinbase Global Inc shares on Tuesday. The firm sold 46,531 shares through its flagship ARK Innovation ETF. The sale comes as Bitcoin hit a 27-month high of around $57,000.
Benzinga · 02/28 03:35
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
Veracyte’s Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN Clinical Practice Guidelines in Oncology. The test is a prognostic tool for the risk stratification of patients with localized prostate cancer.
Barchart · 02/27 16:55
Analysts’ Top Healthcare Picks: BioCryst (BCRX), Veracyte (VCYT)
TipRanks · 02/27 12:11
U.S. RESEARCH ROUNDUP-Agiliti, Domino's Pizza, Krystal Biotech
Wall Street analysts revise their ratings and price targets on several U.S. Listed companies. Agiliti, Domino's Pizza, Krystal Biotech, and Eli Lilly among companies with revised targets. Agilti cut to hold from buy, while others raise their targets.
Reuters · 02/27 07:31
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
Ark Invest sold shares of cryptocurrency-related companies on Monday. Cathie Wood-led Ark Invest reduced its stake in Robinhood Markets Inc and Coinbase Global Inc. The firm also sold a total of 35,509 shares of Bitcoin in a transaction valued at $6.9 million. On Monday, Bitcoin soared past the $56,000 mark.
Benzinga · 02/27 03:45
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $21
Benzinga · 02/26 16:16
Weekly Report: what happened at VCYT last week (0219-0223)?
Weekly Report · 02/26 10:15
More
Webull provides a variety of real-time VCYT stock news. You can receive the latest news about Veracyte through multiple platforms. This information may help you make smarter investment decisions.
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.